Abstract

FRANCO, Juan-Sebastian; CALDERON-OSPINA, Carlos Alberto  and  LOPEZ-CABRA, Claudia Alejandra. New pharmacological approaches in the management of stable angina. Medicas UIS [online]. 2016, vol.29, n.3, pp.79-93. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v29n3-2016009.

In recent years, new antianginal agents with novel mechanisms of action have been launched to the market, as a complement to the existing therapeutic arsenal. Even though the beta-blockers, calcium channel blockers and nitrates continue to be the first line of treatment, recent discoveries of pathophysiological aspects of the disease led to the development of innovative therapeutic targets on both cellular and molecular level. Nicorandil, trimetazidine, ivabradine and ranolazine are novel antianginal drugs and constitute the second line of treatment of stable angina; these drugs are indicated for those patients who persist symptomatic despite treatment with first line agents or in those with contraindication or intolerance to beta-blockers o calcium channel blockers. Trimetazidine, through its metabolic mechanism of action, improves exercise tolerance and might be useful in patients with concomitant heart failure and contraindication to digitalis; ivabradine can be used in patients with concomitant tachyarrhythmias due to its negative chronotropic effect without affecting inotropism or blood pressure; in contrast, ranolazine doesn’t affect chronotropism and can be used in patients with bradyarrhythmias, however, it might cause prolongation of the QTc interval. The choice of treatment with either of the first line or second line antianginal agents must be individualized for each patient and based on comorbidities, contraindications and patient’s preference. MÉD.UIS. 2016;29(3):79-93.

Keywords : Angina Pectoris; Coronary Disease; Cardiovascular Agents; Nicorandil; Trimetazidine; Ranolazine..

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )